Market Place
Sourcing Support
Astellas Showcases Geographic Atrophy Findings At ARVO 2026
30 Apr 2026 //
PR NEWSWIRE
Astellas Closes Stem Cell Unit`s Seattle Site, Layoffs Incoming
14 Apr 2026 //
FIERCE BIOTECH
Astellas, Dyno Unearth $15M Muscle Disorder Capsid
08 Apr 2026 //
FIERCE BIOTECH
Astellas axes early trial for Sjögren’s syndrome
30 Mar 2026 //
FIERCE BIOTECH
Astellas Ends $1.6B Biobucks TCE Pact With Cytomx After 6 Years
17 Mar 2026 //
FIERCE BIOTECH
PADCEV + Keytruda Cuts Recurrence, Death Risk in Bladder Cancer
27 Feb 2026 //
PHARMIWEB
Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151
25 Feb 2026 //
PR NEWSWIRE
Astellas says ‘I do’ to Vir’s T-cell engager in $1.7 billion deal
24 Feb 2026 //
FIERCE PHARMA
Astellas Lifts Forecast As Vyloy Surge Counters Trial Miss
05 Feb 2026 //
FIERCE PHARMA
Ocugen Update Charts Course For Rivalry With Apellis, Astellas
15 Jan 2026 //
FIERCE BIOTECH
VYLOY Enhances Survival With Effective Adverse Event Management
08 Jan 2026 //
PR NEWSWIRE
Astellas` PADCEV And Keytruda Boost Survival in Bladder Cancer
17 Dec 2025 //
PR NEWSWIRE
Astellas to Present New GI Cancers Data at 2026 ASCO GI Symposium
10 Dec 2025 //
PR NEWSWIRE
Astellas To Unveil XOSPATA Data On FLT3M+ AML At ASH 2025 Meeting
05 Dec 2025 //
PR NEWSWIRE
FDA Approves Padvec & Keytruda Combo For Bladder Cancer
21 Nov 2025 //
BUSINESSWIRE
Astellas Turns Down Option To License Taysha Gene Therapy—Again
17 Oct 2025 //
FIERCE BIOTECH
Astellas Showcases Innovations At ESMO 2025
01 Oct 2025 //
PR NEWSWIRE
Padcev-Keytruda Combo Delivers Bladder Cancer `breakthrough`
13 Aug 2025 //
PRESS RELEASE
Astellas, Korean Gov’t Launch Startup Partnership Program
17 Jul 2025 //
PR NEWSWIRE
Xtandi Plus Leuprolide Improves Outcomes in nmHSPC-HRBR
10 Jul 2025 //
BUSINESSWIRE
Astellas offers lab space to help Japanese biotechs `go global`
13 Jun 2025 //
FIERCE BIOTECH
Astellas aims for CLDN18.2 gold with $1.34B licensing deal
29 May 2025 //
PR NEWSWIRE
Padcev now available in India for advanced urothelial cancer
22 Apr 2025 //
EXPRESSPHARMA
Ferring Pharma & Astellas/Pfizer Alliance to End Bladder Cancer
15 Apr 2025 //
PR NEWSWIRE
Singlera Presented Toxicity Detection with Astellas at SOT Meeting
24 Mar 2025 //
GLOBENEWSWIRE
Astellas, YASKAWA to Establish Joint Venture for Cell Therapy
05 Mar 2025 //
PR NEWSWIRE
FDA Expands Label For Astellas’ IZERVAY In Geographic Atrophy
12 Feb 2025 //
PR NEWSWIRE
Pfizer & Astellas Padcev + Keytruda Shows Efficacy in Cancer
10 Feb 2025 //
BUSINESSWIRE
Astellas Submit NDA for Conditional Approval of Avacincaptad
05 Feb 2025 //
PR NEWSWIRE
China`s NMPA Approves Padcev + Keytruda for Advanced Bladder Cancer
08 Jan 2025 //
PR NEWSWIRE
FDA Class 1 Resubmission of Izervay for Geographic Atrophy
08 Jan 2025 //
PR NEWSWIRE
Astellas & Sangamo License Capsid for Neurological Genomic Medicine
19 Dec 2024 //
PR NEWSWIRE
Sangamo & Astellas Announce Capsid License for Gene Therapies
19 Dec 2024 //
BUSINESSWIRE
Astellas pays Sangamo $20M to boost neurological gene therapies
19 Dec 2024 //
FIERCE BIOTECH
Onco360 Selected as National Specialty Pharmacy for Vyloy
26 Nov 2024 //
GLOBENEWSWIRE
FDA approves Astellas` gastric cancer therapy
19 Oct 2024 //
REUTERS
Astellas telegraphs new cell therapy site in Japan, 24 US layoffs
09 Oct 2024 //
FIERCE BIOTECH
Astellas pays $50M for option on AviadoBio dementia gene therapy
08 Oct 2024 //
FIERCE BIOTECH
Singlera And Astellas Present Toxicity Detection At JSOT Meeting
01 Oct 2024 //
BUSINESSWIRE
Japan Approves PADCEV With KEYTRUDA For Urothelial Cancer
24 Sep 2024 //
PR NEWSWIRE
EU Approves Astellas` VYLOY For Gastric Cancers
20 Sep 2024 //
PR NEWSWIRE
Astellas Opens Massachusetts Lab For Biotech And Academia Sharing
05 Sep 2024 //
FIERCE BIOTECH
Astellas Gene Therapies to Shut Down South San Francisco Production Plant
04 Sep 2024 //
FIERCE PHARMA
EC Approves Astellas` PADCEV With KEYTRUDA For Advanced Urothelial Cancer
27 Aug 2024 //
PR NEWSWIRE
China NMPA Approves PADCEV For Advanced Urothelial Cancer
19 Aug 2024 //
PR NEWSWIRE
Astellas` gastric cancer therapy gets UK regulator`s nod
15 Aug 2024 //
ECONOMICTIMES
US FDA acknowledges Astellas` resubmission of BLA for Zolbetuximab
03 Jun 2024 //
PHARMABIZ
FDA Sets New Date For Astellas` Zolbetuximab BLA Resubmission
30 May 2024 //
PR NEWSWIRE
Astellas, YASKAWA Collaborate On Cell Therapy Robotics Integration
21 May 2024 //
PR NEWSWIRE
Astellas partners with Yaskawa to create innovative cell therapy ecosystem
21 May 2024 //
BIOSPECTRUM ASIA
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
02 May 2024 //
PR NEWSWIRE
Astellas, Poseida Collaborate On Allogeneic Cell Therapies In Oncology
01 May 2024 //
PR NEWSWIRE
Astellas` Friedreich’s ataxia gene therapy cleared for clinical study
24 Apr 2024 //
ENDPTS
Astellas writes down another piece of its Audentes gene therapy acquisition
16 Apr 2024 //
ENDPTS
Invenra Inc. Partners with Astellas Pharma for Bispecific Antibody Discovery
09 Apr 2024 //
BUSINESSWIRE
China Accepts Astellas for enfortumab vedotin with KEYTRUDA for Bladder Cancer
28 Mar 2024 //
PR NEWSWIRE
Astellas pursues ‘convertible’ in vivo CAR-T cell therapies with Kelonia
16 Feb 2024 //
ENDPTS
PADCEV with KEYTRUDA Granted Priority Review by Japan`s Ministry of Health
15 Feb 2024 //
PR NEWSWIRE
Astellas Submits sNDA in Japan for PADCEV with KEYTRUDA for Bladder Cancer
30 Jan 2024 //
PR NEWSWIRE
Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
08 Jan 2024 //
PR NEWSWIRE
